Patient characteristics at diagnosis
| Characteristic . | Quantity . |
|---|---|
| Sex, M/F | 47:39 |
| Median age, y (range) | 52 (18-76) |
| Age over 60 years, n (%) | 31 (36) |
| WBC, 109/L (range) | 5.3 (0.9-267) |
| Platelets, 109/L (range) | 59 (5-361) |
| Circulating blasts, % (range) | 22.5 (0-97) |
| BM blasts, % (range) | 64 (21-99) |
| LDH, U/L (range) | 311 (83-3343) |
| Chromosome risk group, no. (%)* | |
| Good | 10 (12) |
| Intermediate | 63 (73) |
| Poor | 12 (14) |
| Failed | 1 (∼1) |
| FAB, no. (∼%) | |
| M0 | 7 (8) |
| M1 | 18 (21) |
| M2 | 29 (34) |
| M4/M4e0 | 18 (21)/3 (3.5) |
| M5a/M5b | 8 (9.5) |
| M6 | 1 (∼1) |
| AML unclassified, no. (%) | 2 (∼2) |
| De novo - secondary | 80:6 |
| Characteristic . | Quantity . |
|---|---|
| Sex, M/F | 47:39 |
| Median age, y (range) | 52 (18-76) |
| Age over 60 years, n (%) | 31 (36) |
| WBC, 109/L (range) | 5.3 (0.9-267) |
| Platelets, 109/L (range) | 59 (5-361) |
| Circulating blasts, % (range) | 22.5 (0-97) |
| BM blasts, % (range) | 64 (21-99) |
| LDH, U/L (range) | 311 (83-3343) |
| Chromosome risk group, no. (%)* | |
| Good | 10 (12) |
| Intermediate | 63 (73) |
| Poor | 12 (14) |
| Failed | 1 (∼1) |
| FAB, no. (∼%) | |
| M0 | 7 (8) |
| M1 | 18 (21) |
| M2 | 29 (34) |
| M4/M4e0 | 18 (21)/3 (3.5) |
| M5a/M5b | 8 (9.5) |
| M6 | 1 (∼1) |
| AML unclassified, no. (%) | 2 (∼2) |
| De novo - secondary | 80:6 |
BM indicates bone marrow; LDH, lactate dehydrogenase; and FAB, French-American-British.
Favorable risk group was defined by presence of t(8;21) or inv (16)/t(16;16). In patients lacking these favorable changes, the presence of a complex karyotype, −5, del(5q), −7, or abnormalities of 3q define a poor risk group. All other chromosomal changes or a normal karyotype define the intermediate risk group.1